Susana Hernandez-Garcia
Overview
Explore the profile of Susana Hernandez-Garcia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
172
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Paino T, Gonzalez-Mendez L, San-Segundo L, Corchete L, Hernandez-Garcia S, Diaz-Tejedor A, et al.
Cancers (Basel)
. 2020 Sep;
12(10).
PMID: 32987735
Background: Proviral Insertion site for Moloney murine leukemia virus (PIM) kinases are overexpressed in hematologic malignancies, including multiple myeloma. Previous preclinical data from our group demonstrated the anti-myeloma effect of...
2.
Algarin E, Hernandez-Garcia S, Garayoa M, Ocio E
Expert Opin Investig Drugs
. 2019 Dec;
29(1):5-14.
PMID: 31815551
: Kinesin spindle protein (KSP) is indispensable for the proper separation of spindle poles during mitosis. Importantly, this protein is expressed only in cells undergoing cell division and hence represents...
3.
Algarin E, Diaz-Tejedor A, Mogollon P, Hernandez-Garcia S, Corchete L, San-Segundo L, et al.
Haematologica
. 2019 Jul;
105(3):e116-e120.
PMID: 31320555
No abstract available.
4.
Hernandez-Garcia S, San-Segundo L, Gonzalez-Mendez L, Corchete L, Misiewicz-Krzeminska I, Martin-Sanchez M, et al.
Haematologica
. 2017 Sep;
102(12):2113-2124.
PMID: 28860344
Kinesin spindle protein inhibition is known to be an effective therapeutic approach in several malignancies. Filanesib (ARRY-520), an inhibitor of this protein, has demonstrated activity in heavily pre-treated multiple myeloma...
5.
Lopez-Iglesias A, Herrero A, Chesi M, San-Segundo L, Gonzalez-Mendez L, Hernandez-Garcia S, et al.
J Hematol Oncol
. 2017 Jun;
10(1):127.
PMID: 28633670
Background: Despite recent advances in the treatment of multiple myeloma (MM), the prognosis of most patients remains poor, and resistance to traditional and new drugs frequently occurs. EDO-S101 is a...
6.
Lopez-Iglesias A, Gonzalez-Mendez L, San-Segundo L, Herrero A, Hernandez-Garcia S, Martin-Sanchez M, et al.
Haematologica
. 2016 Aug;
102(1):168-175.
PMID: 27540138
Despite new advances in multiple myeloma treatment and the consequent improvement in overall survival, most patients relapse or become refractory to treatment. This suggests that new molecules and combinations that...
7.
Paino T, Garcia-Gomez A, Gonzalez-Mendez L, San-Segundo L, Hernandez-Garcia S, Lopez-Iglesias A, et al.
Clin Cancer Res
. 2016 Jul;
23(1):225-238.
PMID: 27440267
Purpose: PIM kinases are a family of serine/threonine kinases recently proposed as therapeutic targets in oncology. In the present work, we have investigated the effects of the novel pan-PIM kinase...
8.
Diaz-Rodriguez E, Hernandez-Garcia S, Sanz E, Pandiella A
Oncotarget
. 2016 Jan;
7(5):6231-42.
PMID: 26756220
Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy whose incidence is growing in developed countries. In the relapse setting, very limited therapeutic options are available and in most cases...
9.
Hernandez-Garcia S, Gonzalez V, Sanz E, Pandiella A
Nutr Cancer
. 2015 Aug;
67(7):1159-69.
PMID: 26241555
One of the most aggressive breast cancer subtypes includes tumors with high expression of HER2. Gene expression and functional studies have shown a link between HER2 overexpression and oxidative stress....
10.
Iglesias J, Leis O, Perez Ruiz E, Gumuzio Barrie J, Garcia-Garcia F, Aduriz A, et al.
Front Oncol
. 2014 Nov;
4:308.
PMID: 25414831
The striking similarity displayed at the mechanistic level between tumorigenesis and the generation of induced pluripotent stem cells and the fact that genes and pathways relevant for embryonic development are...